Vemurafenib

Vemurafenib - most related articles:

- Intermittent dosing with vemurafenib may prolong lives of melanoma patients - 6
- New melanoma drug doubles survival of skin cancer patients - 4.9
- Zelboraf approved for late stage skin cancer - 2.4

Vemurafenib articles

Intermittent dosing with vemurafenib may prolong lives of melanoma patients
Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease.

New melanoma drug doubles survival of skin cancer patients
Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

Zelboraf approved for late stage skin cancer
The U.S. Food and Drug Administration recently approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

3 Vemurafenib articles listed above.


Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.
Subscribe: rss | email

Top sections:
Health (188)
Breast cancer (168)
Healthcare (134)
HIV (129)
Obesity (126)
Pregnancy (114)
Diabetes (101)
Swine Flu (97)
Prostate Cancer (86)
Heart disease (84)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (52)


List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2014 HealthNewstrack.com
2.94